annual cash & cash equivalents:
$97.25M-$89.48M(-47.92%)Summary
- As of today (July 1, 2025), PTGX annual cash & cash equivalents is $97.25 million, with the most recent change of -$89.48 million (-47.92%) on December 31, 2024.
- During the last 3 years, PTGX annual cash & cash equivalents has fallen by -$26.42 million (-21.36%).
- PTGX annual cash & cash equivalents is now -47.92% below its all-time high of $186.73 million, reached on December 31, 2023.
Performance
PTGX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$139.65M+$42.40M(+43.60%)Summary
- As of today (July 1, 2025), PTGX quarterly cash & cash equivalents is $139.65 million, with the most recent change of +$42.40 million (+43.60%) on March 1, 2025.
- Over the past year, PTGX quarterly cash & cash equivalents has dropped by -$32.91 million (-19.07%).
- PTGX quarterly cash & cash equivalents is now -60.73% below its all-time high of $355.64 million, reached on June 30, 2024.
Performance
PTGX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PTGX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.9% | -19.1% |
| 3 y3 years | -21.4% | +41.8% |
| 5 y5 years | +194.6% | +131.9% |
PTGX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.9% | at low | -60.7% | +43.6% |
| 5 y | 5-year | -47.9% | +194.6% | -60.7% | +68.3% |
| alltime | all time | -47.9% | +2298.3% | -60.7% | +3344.0% |
PTGX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $139.65M(+43.6%) |
| Dec 2024 | $97.25M(-47.9%) | $97.25M(-25.8%) |
| Sep 2024 | - | $131.12M(-63.1%) |
| Jun 2024 | - | $355.64M(+106.1%) |
| Mar 2024 | - | $172.57M(-7.6%) |
| Dec 2023 | $186.73M(+48.5%) | $186.73M(-19.0%) |
| Sep 2023 | - | $230.53M(-2.1%) |
| Jun 2023 | - | $235.38M(+84.3%) |
| Mar 2023 | - | $127.69M(+1.5%) |
| Dec 2022 | $125.74M(+1.7%) | $125.74M(-17.7%) |
| Sep 2022 | - | $152.82M(+27.1%) |
| Jun 2022 | - | $120.24M(+22.1%) |
| Mar 2022 | - | $98.48M(-20.4%) |
| Dec 2021 | $123.67M(+5.4%) | $123.67M(+2.6%) |
| Sep 2021 | - | $120.54M(-37.4%) |
| Jun 2021 | - | $192.41M(+131.8%) |
| Mar 2021 | - | $83.00M(-29.3%) |
| Dec 2020 | $117.36M | $117.36M(+40.3%) |
| Sep 2020 | - | $83.63M(-42.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $146.24M(+142.9%) |
| Mar 2020 | - | $60.22M(+82.4%) |
| Dec 2019 | $33.01M(-59.9%) | $33.01M(-34.2%) |
| Sep 2019 | - | $50.20M(-29.4%) |
| Jun 2019 | - | $71.14M(+1.5%) |
| Mar 2019 | - | $70.08M(-14.8%) |
| Dec 2018 | $82.23M(-22.4%) | $82.23M(-5.9%) |
| Sep 2018 | - | $87.43M(+36.9%) |
| Jun 2018 | - | $63.86M(-8.2%) |
| Mar 2018 | - | $69.58M(-34.4%) |
| Dec 2017 | $106.03M(+402.9%) | $106.03M(+110.4%) |
| Sep 2017 | - | $50.40M(+386.2%) |
| Jun 2017 | - | $10.37M(+8.9%) |
| Mar 2017 | - | $9.52M(-54.9%) |
| Dec 2016 | $21.08M(+420.0%) | $21.08M(-78.0%) |
| Sep 2016 | - | $96.02M(+597.4%) |
| Jun 2016 | - | $13.77M(-51.9%) |
| Mar 2016 | - | $28.63M(+606.0%) |
| Dec 2015 | $4.05M(-56.5%) | $4.05M |
| Dec 2014 | $9.32M | - |
FAQ
- What is Protagonist Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual cash & cash equivalents year-on-year change?
- What is Protagonist Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Protagonist Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PTGX is $97.25M
What is the all time high annual cash & cash equivalents for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash & cash equivalents is $186.73M
What is Protagonist Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PTGX annual cash & cash equivalents has changed by -$89.48M (-47.92%)
What is Protagonist Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of PTGX is $139.65M
What is the all time high quarterly cash & cash equivalents for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash & cash equivalents is $355.64M
What is Protagonist Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, PTGX quarterly cash & cash equivalents has changed by -$32.91M (-19.07%)